Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency

FDA approved avatrombopag for thrombocytopenia in CLD patients scheduled for a procedure

/1 Comment/in /by

 

You might also like
Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency Everolimus suspension approved in TSC-associated partial-onset seizures
Pembrolizumab plus chemotherapy approved for metastatic squamous NSCLC
Glasdegib plus low-dose cytarabine (LDAC) approved in elderly AML patients
Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency Combination encorafenib plus binimetinib for unresectable/metastatic BRAF V600E or V600K-positive melanoma FDA approved
us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious.jpg Nivolumab approved for sorafenib-refractory HCC
©aquir / 123RF Stock Photo FDA approved a broadened indication of afatinib in the 1st-line treatment of metastatic NSCLC with non-resistant EGFR mutations
Dacomitinib FDA approved for the first-line treatment of metastatic EGFR-mutated NSCLC
Trastuzumab/hyaluronidase-oysk subcutaneous formulation FDA approved for HER2‑overexpressing breast cancer
1 reply

Trackbacks & Pingbacks

  1. FDA approved avatrombopag for thrombocytopenia in CLD patient scheduled for a procedure - MediNews Asia says:
    23rd May 2018 at 11:47 PM

    […] post FDA approved avatrombopag for thrombocytopenia in CLD patient scheduled for a procedure appeared first on Medical Writer Agency | 香港醫學作家 | MediPR | MediPaper Hong […]

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply